Although currently standard practice does not include genetic testing for prostate cancer screening, reports of increased prostate cancer risk in men with mutations in BRCA1 and BRCA2 have been published.49–54 Increased risk has also been noted in the mismatch repair (MMR) gene mutation carriers.55 Clinical genetic testing is available, but its use in screening remains to be defined. This evidence concerns the gene BRCA1 and Familial prostate cancer.